- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04625517
Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM)
This study is designed to investigate the diagnostic accuracy of Contrast Enhanced Spectral Mammography (CEDM) in predicting early neoadjuvant therapy response and pathologic complete response (pCR) compared to mammography.
Patients diagnosed with invasive breast cancer with available mammography and ultrasound imaging are eligible for the study.
Eligible patients will be imaged at baseline (before initiation of neoadjuvant chemotherapy or endocrine therapy), early (2-4 cycles of neoadjuvant therapy) and late (after completion of neoadjuvant chemotherapy or endocrine therapy) timepoints with mammography. CEDM will be done within 2 weeks of the specified timepoint. Additionally, a survey of subject experience with CEDM and other pre-operative imaging will be collected after CEDM is performed.
Study Overview
Status
Conditions
Detailed Description
The use of neoadjuvant systemic therapy in the treatment of breast cancer patients is increasing beyond the scope of locally advanced disease. Imaging provides important information in assessing response to therapy as a complement to conventional tumor measurements via physical examination. Tumor response to neoadjuvant therapy can also provide prognostic information. The attainment of pCR after completion of neoadjuvant therapy and surgical resection is associated with improved disease-free survival. This correlation is especially strong for Triple-receptor negative and human epidermal growth factor receptor 2 (HER-2) positive breast cancer. Studies of neoadjuvant therapy have used a variety of methods for assessing tumor response. Currently, there are no established clinical practice guidelines for how best to assess tumor response to neoadjuvant therapy. Typically, patients undergo conventional breast imaging such as mammography and ultrasonography (US) and physical examination, and dynamic contrast-enhanced breast magnetic resonance imaging (DCR-MRI) in selected cases.
Contrast Enhanced Digital Mammography (CEDM) is a novel imaging technique, which allows digital mammography to be used with contrast enhancement to depict cancers that would otherwise be occult on standard unenhanced mammography. CEDM is performed with and without intravenous iodine contrast, using the dual energy subtraction technique. Compared with mammography and US, CEDM improves the sensitivity for breast cancer detection without decreasing specificity. CEDM digital detector has higher spatial resolution than MRI, revealing details that are approximately 10 times better. In contrast to the rapid washout in MRI, enhancement on CEDM in fact persists for at least 10 min after contrast agent infusion. Today CEDM is available commercially for clinical use. It is estimated that over 200,000 CEDM examinations have been performed to date in both research and clinical settings. CEDM costs significantly less compared to MRI. Furthermore, longer time delays between contrast injection and CEDM exposure could result in stronger enhancement and hence better visibility compared to MRI, especially given the much higher spatial resolution of digital mammography. It is unknown whether CEDM can improve the sensitivity of mammography in the early assessment of neoadjuvant therapy response. We hypothesize that CEDM is superior to mammography and ultrasound in assessing early response, and pre-surgical residual cancer after neoadjuvant therapy, and when performed, non-inferior to MRI in assessing the residual disease using the metrics of pCR and residual cancer burden (RCB).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ipsilateral intact biopsy-proven breast cancer clinical stage T1-T4 (by imaging)
- Available mammography and ultrasound imaging of the existing index cancer, with orthogonal measurements
- Prior history of ipsilateral or contralateral breast cancer, presenting with a new primary or recurrent disease
- Patients who were determined to be candidates for either neoadjuvant chemotherapy or neoadjuvant endocrine therapy by the treating physician
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for days following completion of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
Exclusion Criteria:
- History of ipsilateral mastectomy
- Women who already started neoadjuvant chemotherapy or endocrine therapy
- Woman who may be pregnant or nursing an infant
- Prior history of anaphylactic or anaphylactoid reaction to any contrast.
- Prior allergy to iodine or iodinated contrast.
- Impaired renal function measured by estimated glomerular filtration rate (eGFR) < 60 milliliters per minute.
- Patients with known distant metastasis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Breast cancer patients
Patients with ipsilateral intact biopsy-proven breast cancer
|
Digital Mammography enhanced with an iodinated contrast agent
Injection of low osmolar contrast material during the digital mammography exam
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity of Predicting pCR (Pathologic Complete Response) for CEDM
Time Frame: 4 to 6 months from initiation of neoadjuvant therapy until final surgery
|
Sensitivities in predicting pCR will be calculated for CEDM and measured as AUC
|
4 to 6 months from initiation of neoadjuvant therapy until final surgery
|
Sensitivity of Predicting pCR (Pathologic Complete Response) for Mammography
Time Frame: 4 to 6 months from initiation of neoadjuvant therapy until final surgery
|
Sensitivities in predicting pCR will be calculated for mammography measured as AUC
|
4 to 6 months from initiation of neoadjuvant therapy until final surgery
|
Specificity of Predicting pCR (Pathologic Complete Response) for CEDM
Time Frame: 4 to 6 months from initiation of neoadjuvant therapy until final surgery
|
Specificity of predicting pCR will be calculated for CEDM and measured as AUC
|
4 to 6 months from initiation of neoadjuvant therapy until final surgery
|
Specificity of Predicting pCR (Pathologic Complete Response) for Mammography
Time Frame: 4 to 6 months from initiation of neoadjuvant therapy until final surgery
|
Specificity of predicting pCR will be calculated for mammography and measured as AUC
|
4 to 6 months from initiation of neoadjuvant therapy until final surgery
|
Diagnostic Accuracy of Contrast-enhanced Mammography in Assessing pCR or Non Response
Time Frame: 4 to 6 months from initiation of neoadjuvant therapy until final surgery
|
ROC analysis will be used to assess the diagnostic performance of CEDM.
The Area under the receiver operating characteristic (ROC) curve (AUC) will be compared.
A leave-one-out cross validation algorithm will be used to reduce bias from overfitting.
|
4 to 6 months from initiation of neoadjuvant therapy until final surgery
|
Correlation of Residual Tumor Size With Pathologic Size
Time Frame: 4 to 6 months from initiation of neoadjuvant therapy until final surgery
|
Spearman's rank correlation will be used to measure the association between final pathologic and imaging tumor size
|
4 to 6 months from initiation of neoadjuvant therapy until final surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To identify any patient preference differences between CEDM and breast MRI
Time Frame: Up to 4 years
|
A survey will be administered to each patient who undergo both breast MRI and contrast enhanced mammography to assess their preference.
|
Up to 4 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Basak Dogan, MD, UT Southwestern Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- STU-2019-0529
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Digital Mammography
-
American College of Radiology Imaging NetworkNational Cancer Institute (NCI)Completed
-
Planmed OyWithdrawnBreast CancerUnited States
-
University of MichiganCompleted
-
GE HealthcareCompleted
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI); Canadian Cancer Trials Group (CCTG)RecruitingBreast ScreeningUnited States, Canada, Puerto Rico, Argentina, Korea, Republic of
-
Universitaire Ziekenhuizen KU LeuvenUnknown
-
Boston Medical CenterUnited States Department of DefenseCompletedBreast CancerUnited States
-
Cancer Registry of NorwayUniversity of Oslo; The Research Council of Norway; Haukeland University HospitalCompleted
-
University of Alabama at BirminghamCompleted
-
Emory UniversityBBN TechnologiesCompleted